Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Bradmer Pharmaceuticals reports loss of $0.059 per share
January 29th, 2007
Bradmer Pharmaceuticals, Inc., a clinical oncology company specializing in the development and commercialization cancer therapies, announced its 2006 third quarter operational and financial results. During the 3-month period ended September 30, 2006, the company achieved the following steps in preparation for the upcoming multicenter trial for Neuradiab and its subsequent planned commercialization: 1) Recruited Alan M. Ezrin, PhD, to join the company as chief operating officer. 2) Submitted a request to the U.S. Food and Drug Administration (FDA) for an end of phase II meeting on Neuradiab. 3) Submitted an E.U....
Source: Biotech Business Week (2007-01-29)
|
